Condition
Mycobacterium
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Terminated1
Enrolling By Invitation1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06809413Phase 2Enrolling By Invitation
Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease
NCT05030701UnknownPrimary
Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
NCT01200992Phase 3Terminated
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
Showing all 3 trials